These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17710597)

  • 21. Pushing drugs to doctors.
    Consum Rep; 1992 Feb; 57(2):87-94. PubMed ID: 11651202
    [No Abstract]   [Full Text] [Related]  

  • 22. Health risk communication using comparative risk analyses.
    Williams PR
    J Expo Anal Environ Epidemiol; 2004 Nov; 14(7):498-515. PubMed ID: 15254483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Communicating food risks in an era of growing public distrust: three case studies.
    Lofstedt R
    Risk Anal; 2013 Feb; 33(2):192-202. PubMed ID: 22050421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 26. Consumers' preferences for the communication of risk information in drug advertising.
    Davis JJ
    Health Aff (Millwood); 2007; 26(3):863-70. PubMed ID: 17485767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Internet strategies being implemented by pharmaceutical companies.
    Goldstein D; Flory J
    Med Interface; 1997 May; 10(5):48-50. PubMed ID: 10167503
    [No Abstract]   [Full Text] [Related]  

  • 28. Taking behavioralism seriously: some evidence of market manipulation.
    Hanson JD; Kysar DA
    Harv Law Rev; 1999 May; 112(7):1420-572. PubMed ID: 10558427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RU 486 and the politics of drug regulation in the United States and France.
    Kramnick RK
    Cornell Int Law J; 1992; 25():667-718. PubMed ID: 11656340
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk communication--the perceptions and realities.
    Trautman TD
    Food Addit Contam; 2001 Dec; 18(12):1130-4. PubMed ID: 11761125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The public and effective risk communication.
    Frewer L
    Toxicol Lett; 2004 Apr; 149(1-3):391-7. PubMed ID: 15093286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of qualifying language on perceptions of drug appeal, drug experience, and estimates of side-effect incidence in DTC advertising.
    Davis J
    J Health Commun; 2007; 12(7):607-22. PubMed ID: 17934939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
    Mackler BF; Barach M
    J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Playing "kick the FDA"--risk-free to players but hazardous to public health.
    Wood AJ
    N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
    [No Abstract]   [Full Text] [Related]  

  • 37. Obesity--the new frontier of public health law.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2006 Jun; 354(24):2601-10. PubMed ID: 16775242
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmaceutical marketing and the new social media.
    Greene JA; Kesselheim AS
    N Engl J Med; 2010 Nov; 363(22):2087-9. PubMed ID: 21105789
    [No Abstract]   [Full Text] [Related]  

  • 40. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.